Dyne Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
DYN$17.92-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(65,649) | $(44,187) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation expense | 19,906 | 4,617 |
| Depreciation and amortization expense | 386 | 412 |
| Non-cash lease expense | 173 | 211 |
| Accretion of premium on marketable securities | (523) | (181) |
| Loss on sale of marketable securities | — | 23 |
| Loss (gain) on disposal of property and equipment | (2) | 118 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (4,070) | (1,390) |
| Accounts payable and other liabilities | (28,758) | (6,531) |
| Net cash used in operating activities | (78,537) | (46,908) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (191) | (230) |
| Purchases of marketable securities | (181,386) | (16,687) |
| Maturities of marketable securities | 1,740 | 42,150 |
| Sales of marketable securities | — | 1,829 |
| Net cash (used in) provided by investing activities | (179,837) | 27,062 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in public offering, net of issuance costs | 323,851 | — |
| Proceeds from issuance of common stock in at-the-market offering, net of issuance costs | 73,621 | 28,228 |
| Proceeds from exercise of stock options | 10,916 | 587 |
| Net cash provided by financing activities | 408,388 | 28,815 |
| Net increase in cash, cash equivalents and restricted cash | 150,014 | 8,969 |
| Cash, cash equivalents and restricted cash, beginning of period | 123,941 | 174,466 |
| Cash, cash equivalents and restricted cash, end of period | $273,955 | $183,435 |
| Supplemental disclosures of cash flow information: | ||
| Proceeds from issuance of common stock in at-the-market offering in other receivables | $24,250 | $— |
| Public offering costs in accounts payable and accrued expenses | $— | $42 |
| Purchase of property and equipment in accounts payable | $27 | $39 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.